Therapy Areas: AIDS & HIV
New Food Allergy Diagnostics, AllerGenis, Recently Launched to Deliver Innovative Diagnostic Technology Enabling More Precise Food Allergy Detection and Patient Management
26 September 2018 - - New US-based food allergy diagnostics company, AllerGenis, LLC recently launched for the purpose of bringing innovative, precision diagnostic solutions to food allergy clinicians, with the goal of improving patient outcomes through highly accurate and safe diagnostic tools.

The market for food allergy diagnostics is substantial, with 15m Americans reportedly having food allergies, including 8% of all children.

Moreover, one in 13 children in the US are at risk for life-threatening anaphylaxis.

Yet, current food allergy diagnostics have very low accuracy, and as many as 60% of patients may be misdiagnosed.

AllerGenis has developed its technology using data-driven machine learning and next-generation multiplex immunoassay technology to more precisely diagnose and monitor patients with food allergies.

It will be one of the first non-oncologic, precision medicine tools to help providers better diagnose, assess, and manage patients with food allergies.

AllerGenis' diagnostics next-generation technology uses a proprietary epitope mapping platform developed by Hugh Sampson MD, of the Elliot and Roslyn Jaffe Food Allergy Institute of the Icahn School of Medicine at Mount Sinai.

The platform is a high-throughput, peptide-bead assay, which subdivides allergenic proteins into smaller peptides, called epitopes, and measures the reactivity of a patient's IgE/IgG4 levels to these epitopes.

Each patient will have a reactivity profile, known as an epitope signature, guiding providers with information to better assess and manage patients' food allergies.

The first product to be launched using this proprietary technology platform will be the company's peanut allergy assay, which will be available in the fall of 2019.

Moving forward, AllerGenis plans to develop a pipeline of assays across food allergens.

Established in 2017 and located in Hatfield, PA, AllerGenis develops precision, data-driven diagnostics to help healthcare providers more accurately and safely diagnose, assess and monitor patients with food allergies.

The company was founded out of a collaboration between Genisphere, a provider of the 3DNA platform for targeted drug delivery, and Hugh Sampson MD, of the Elliot and Roslyn Jaffe Food Allergy Institute of the Icahn School of Medicine at Mount Sinai. It leverages Genisphere's Luminex bead-based immunoassay technology, which is used to make life science and diagnostics tests more sensitive.

AllerGenis' proprietary epitope mapping technology is based on immunological research by Dr. Sampson. AllerGenis is creating the largest food allergy knowledge base populated by individual patient epitope signatures derived from epitope mapping, clinical history, and patient-reported outcomes to gain clinical insights.

The Mount Sinai Health System is New York City's largest integrated delivery system encompassing seven hospital campuses, a leading medical school, and a vast network of ambulatory practices throughout the greater New York region.

Mount Sinai's vision is to produce the safest care, the highest quality, the highest satisfaction, the best access and the best value of any health system in the nation.

The System includes approximately 6,600 primary and specialty care physicians; 11 joint-venture ambulatory surgery centers; more than 140 ambulatory practices throughout the five boroughs of New York City, Westchester, Long Island, and Florida; and 31 affiliated community health centres.